Ultragenyx says Angelman therapy is working, but safety questions remain:
https://www.biopharmadive.com/news/ultragenyx-angelman-gtx-102-interim-results/713169/
Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-45
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.70 |
Change
-0.370(2.63%) |
Mkt cap ! $1.746B | |||
| Open | High | Low | Value | Volume |
| $13.73 | $13.88 | $13.40 | $4.396M | 320.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 312 | $13.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.72 | 546 | 11 |
View Market Depth
| Last trade - 12.14pm 04/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |